An Observational Study for Gastric Cancer in Asymptomatic Carriers of High Risk Helicobacter Pylori
NCT ID: NCT06896370
Last Updated: 2025-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
6000 participants
OBSERVATIONAL
2025-05-01
2035-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fecal Helicobacter Pylori Gene Detection for Gastric Cancer
NCT06943781
Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test
NCT06943768
Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication
NCT01678027
The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer
NCT00596401
Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer
NCT07312500
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Secondary research objectives: 1. To observe and compare the cumulative incidence and progression of gastric precancerous lesions (e.g., atrophic gastritis, intestinal metaplasia, etc.) in each population group during the follow-up period.2. To explore the interaction of high-risk SNPs on the risk of gastric cancer in the context of different age, gender or other risk factors (e.g. diet, smoking, alcohol abuse, family history, etc.).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
exposure group
Hp positive + high risk SNP
observational study
By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
Control 1
Hp positive + non-high risk SNP
observational study
By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
Control 2
Hp negative
observational study
By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
observational study
By prospectively following a population of asymptomatic carriers carrying high-risk Hp SNP subtypes and non-high-risk subtypes, the incidence of gastric cancer and progression of gastric precancerous lesions were compared between the groups.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. No previous history of gastric cancer (no radical surgery or radiotherapy treatment for gastric cancer);
3. Able and willing to provide informed consent and willing to accept baseline and follow-up examinations;
4. Able to cooperate in completing HP testing (breath test, gastroscopic biopsy or other standard testing methods) and HP SNP typing by stool testing;
5. No obvious gastric symptoms at the time of initial screening, no progressive gastric cancer or serious gastric diseases (e.g., perforated acute ulcers, upper gastrointestinal hemorrhage, etc.) detected, and no need for urgent surgery (not planned within 3 months) or other therapeutic interventions for the time being.
Exclusion Criteria
2. Comorbid serious underlying diseases (e.g., severe cardiopulmonary insufficiency, liver and renal failure, etc.) that are expected to have a short survival time or are not suitable for long-term follow-up;
3. Inability to complete or refusal to undergo HP testing, SNP gene testing or follow-up;
4. Presence of severe mental illness or incapacity for civil behavior that prevents completion of the study;
5. Pregnant or breastfeeding women who are temporarily excluded;
6. Other conditions that the investigator considers unsuitable for participation in this study.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dazhi Xu
Dazhi Xu
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025observational study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.